checkAd

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people

Nachrichtenquelle: globenewswire
28.04.2021, 07:00  |  197   |   |   

  • Cardiovascular diseases are responsible for 17.9 million deaths every year¹, a third of all deaths globally²
  • Roche announces five new intended uses for key cardiac biomarkers to help identify cardiovascular risk, better diagnose patients and support early treatment
  • Early diagnosis and treatment can contribute to saving or improving people's lives and could help healthcare systems save money

Handeln Sie Ihre Einschätzung zu Roche Holding AG Inhaber-Genussscheine!
Short
Basispreis 371,73€
Hebel 14,50
Ask 0,25
Long
Basispreis 325,97€
Hebel 14,03
Ask 1,92

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and better manage heart failure⁵ (NT-proBNP). Roche's introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benefit from improved cardiovascular diagnostics. By providing greater precision and certainty for clinicians, Roche can help them tackle the world's biggest killer: cardiovascular diseases.

“The five new solutions we launch this month add real value for clinicians by supporting cardiac risk identification and improving diagnosis. In turn, this will help them make early treatment decisions, improve people’s lives and reduce healthcare costs,” said Thomas Schinecker, CEO Roche Diagnostics. “As the market leader in cardiovascular testing Roche is committed to innovation in cardiovascular care and these new intended uses are the first of many solutions planned over the next decade that could help improve the lives of millions of people.”

One of the new intended uses for Elecsys NT-proBNP supports healthcare professionals in identifying which people with type-2 diabetes (463 million worldwide⁶) are at higher risk of developing cardiovascular disease⁷. Early identification of people at risk means cardioprotective treatment can be started sooner, which could prevent 65% of hospitalisations or deaths⁸. The second newly-launched intended use for NT-proBNP provides healthcare professionals with a biomarker-based solution that identifies people at risk of developing Atrial Fibrillation (AF), an abnormal heart rhythm that can lead to stroke, brain damage and death⁹. More than 37 million people suffer from AF globally¹⁰. NT-proBNP, in combination with a single lead (or higher) electrocardiogram, can help to successfully diagnose AF so therapy can be started to reduce the stroke risk¹¹.

Seite 1 von 6
Roche Holding Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people Cardiovascular diseases are responsible for 17.9 million deaths every year¹, a third of all deaths globally²Roche announces five new intended uses for key cardiac biomarkers to help identify cardiovascular risk, better diagnose patients and support …

Nachrichten des Autors

Titel
Titel
Titel
Titel